A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
- Conditions
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 223
- Registration Number
- NCT01447706
- Locations
- 🇺🇸
Wilshire Oncology Medical Group, Corona, California, United States
🇺🇸Pinnacle Oncology, Scottsdale, Arizona, United States
🇺🇸ProMedica Health System, Inc., Toledo, Ohio, United States
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01447225
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 196
- Registration Number
- NCT01421472
- Locations
- 🇺🇸
Texas Oncology - Dallas, Dallas, Texas, United States
🇺🇸Texas Oncology - Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University Of Chicago, Chicago, Illinois, United States
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT01304784
- Locations
- 🇺🇸
Georgia Cancer Specialists, Atlanta, Georgia, United States
🇺🇸GHS Institute of Transitional Oncology Research, Greenville, South Carolina, United States
🇺🇸Central Indiana Cancer Centers, Indianapolis, Indiana, United States
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT01304797
- Locations
- 🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸Washington University, St. Louis, Missouri, United States
🇺🇸University of Indiana, Indianapolis, Indiana, United States
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2016-09-08
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT01209195
- Locations
- 🇺🇸
Cancer Care Associates of Fresno, Fresno, California, United States
🇺🇸University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT01151046
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇪🇸Puerta de Hierro, Madrid, Spain
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT01097460
- Locations
- 🇺🇸
Indiana University (IUPUI), Indianapolis, Indiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT00994123
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
- Conditions
- Interventions
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00911898
- Locations
- 🇺🇸
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Indiana University (IUPUI), Indianapolis, Indiana, United States
🇺🇸Fox Chase Center, Philadelphia, Pennsylvania, United States